We are live on ! Find out more
CLBT icon

Cellebrite

209 hedge funds and large institutions have $2.33B invested in Cellebrite in 2025 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 82 increasing their positions, 62 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 21

32% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 62

6% more funds holding

Funds holding: 197209 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

0.13% less ownership

Funds ownership: 54.08%53.95% (-0.13%)

3% less capital invested

Capital invested by funds: $2.4B → $2.33B (-$71.7M)

40% less call options, than puts

Call options by funds: $7.55M | Put options by funds: $12.5M

Holders
209
Holders Change
+12
Holders Change %
+6.09%
% of All Funds
2.53%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
35
Increased
82
Reduced
62
Closed
21
Calls
$7.55M
Puts
$12.5M
Net Calls
-$4.98M
Net Calls Change
-$8.97M

CLBT Hedge Fund Activity: Q4 2025 in Review

209 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Cellebrite (CLBT) for Q4 2025, worth a combined $2.33B — down 3% from $2.4B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new CLBT positions and 21 closed out — a net gain of 14 holders — while 82 added to existing stakes and 62 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $59M. The largest seller was Axon Enterprise, cutting an estimated $39M.

  • 209 institutional investors held Cellebrite (CLBT) as of Q4 2025, up from 197 in Q3 2025.
  • Funds reported $2.33B of Cellebrite stock for Q4 2025, down 3% quarter-over-quarter.
  • 35 funds opened new Cellebrite positions in Q4 2025 and 21 closed out, a net change of +14 holders.
  • The largest Cellebrite buyer in Q4 2025 was Fidelity Investments, an estimated $59M added.
  • The largest Cellebrite seller in Q4 2025 was Axon Enterprise, an estimated $39M sold.

Based on aggregated 13F filings for Q4 2025.